Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Discoverie trades in line during Q1, reiterates FY adjusted earnings guidance

(Sharecast News) - Electronics components manufacturer Discoverie said on Thursday that Q1 trading was in line with guidance and said expectations for adjusted earnings for FY25/26 remain unchanged. Discoverie said group sales were 3% higher year-on-year at constant currency, with organic sales flat and acquisitions contributing 3% growth.

Three of Discoverie's four operating units delivered "good levels of organic sales growth". However, this was offset by its controls operating unit, where demand remained subdued.

The FTSE 250-listed group said total orders were 4% lower at constant currency in Q126, following a strong previous quarter and against a strong Q125 comparator. Discoverie also noted that it maintained "a strong order book for delivery" through the remainder of FY26.

"With an excellent pipeline of organic and inorganic opportunities and strong cashflow, the group is well positioned to continue its through-cycle growth as market conditions further stabilise," said Discoverie.

As of 1120 BST, Discoverie shares were down 2.39% at 695.00p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.